Skip to main content
. Author manuscript; available in PMC: 2023 Jul 3.
Published in final edited form as: Sci Transl Med. 2021 May 5;13(592):eabc3196. doi: 10.1126/scitranslmed.abc3196

Figure 5. CAR transduced CD8+CD161+ cells exhibit a killing advantage over CAR transduced bulk PBMC and CD8+CD161− cells.

Figure 5.

(A) HER2+ BT474 (left) and HER2− Raji (right) tumor cells were labelled with 51chromium for 4 hours and co-cultured with indicated CAR T cells. Percent cell lysis was determined by chromium released into the media. NT, non-transduced. (B) Long term cytotoxicity was measured using an xCELLigence impedance-based assay. CFPAC1 tumor cells were seeded at 10,000 cells per well in a 96 well plate in triplicates and allowed to grow over 40 hours. T cells were then added at 2.5:1 tumor cell:T cell ratio and tumor growth or death, as indicated by cell index, was monitored over time. Data are presented as means ± SEM, ****p<0.0001 by one-way ANOVA with Tukey’s post-hoc analysis.